Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of H2 Antagonist and PPI on Selpercatinib PK in Healthy Adults
NCT05338502Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of selpercatinib in non-small cell lung cancer (NSCLC), thyroid cancer and Medullary Thyroid Cancer (MTC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to the Last Observed Non-zero Concentration at Day 23, Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity at Day 23 and 5 more. Started Jul 2019; status: completed.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)thyroid cancerMedullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT05338502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338502.